Cook starts drug-eluting stent trial in US:
This article was originally published in Clinica
Executive Summary
Cook (Bloomington, Indiana) has begun the first clinical trial of its drug-eluting coronary stent for preventing restenoses in the US. The Logic PTX stent, which is coated with the anti-cancer drug, paclitaxel, will be tested in a study of around 800 patients. Enrolment is expected to be concluded in early 2002. The study also represents the first US trial of a paclitaxel-coated stent, says Cook, which has developed a proprietary polymer-free method of coating the stent with the drug.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.